Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NGNE, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|
Also used in these trials (approved or third-party drugs, not NGNE's own candidates): Interleukin-2/Interleukin-15 Receptor Agonist NL-201, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
NGNE holds $359.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $26.5M/quarter from operations, an estimated runway of 40.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 24 · Moderate
Following the completion of our July 2026 public offering, we believe our existing cash, cash equivalents and investments will be sufficient to fund our operations into the first quarter of 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NGNE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| PRUDENTIAL FINANCIAL INC | Institution (13G, 5%+) | 2,231,357 | 10.78% | 2026-09-30 |
| Jennison Associates LLC | Institution (13G, 5%+) | 2,229,082 | 10.77% | 2026-09-30 |
| Srinivas Akkaraju | 5%+ holder (13G) | 1,954,197 | 9.44% | 2026-09-30 |
| RTW Investments, LP | Institution (13G, 5%+) | 1,897,463 | 9.17% | 2026-09-30 |
| Samsara BioCapital GP, LLC 10% owner |
Insider | 1,717,127 | 8.29% | 2024-11-26 |
| Redmile Group, LLC | Institution (13G, 5%+) | 1,572,202 | 7.59% | 2026-06-30 |
| Rachel McMinn Chief Executive Officer, Director · +298,600 options |
Insider | 1,345,063 | 6.50% | 2026-09-22 |
| Christine Mikail Cvijic President and CFO, Director · +253,900 options |
Insider | 84,040 | 0.41% | 2026-07-06 |
| Stuart Cobb Chief Scientific Officer · +42,900 options |
Insider | 30,497 | 0.15% | 2026-03-13 |
| Julie Jordan Chief Medical Officer · +79,900 options |
Insider | 12,472 | 0.06% | 2026-03-26 |
Share count 20,700,905 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NGNE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →